Literature DB >> 30577918

Choosing Core Outcomes for Use in Clinical Trials in Ophthalmology: Perspectives from Three Ophthalmology Outcomes Working Groups.

Ian J Saldanha1, Jimmy T Le2, Sharon D Solomon2, Michael X Repka2, Esen K Akpek2, Tianjing Li2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30577918      PMCID： PMC6474247          DOI： 10.1016/j.ophtha.2018.09.008

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  31 in total

1.  Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases.

Authors:  Ian J Saldanha; Kristina Lindsley; Diana V Do; Roy S Chuck; Catherine Meyerle; Leslie S Jones; Anne L Coleman; Henry D Jampel; Kay Dickersin; Gianni Virgili
Journal:  JAMA Ophthalmol       Date:  2017-09-01       Impact factor: 7.389

Review 2.  TFOS DEWS II Clinical Trial Design Report.

Authors:  Gary D Novack; Penny Asbell; Stefano Barabino; Michael V W Bergamini; Joseph B Ciolino; Gary N Foulks; Michael Goldstein; Michael A Lemp; Stefan Schrader; Craig Woods; Fiona Stapleton
Journal:  Ocul Surf       Date:  2017-07-20       Impact factor: 5.033

Review 3.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes.

Authors:  M A Lemp
Journal:  CLAO J       Date:  1995-10

4.  Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications.

Authors:  Benjamin D Sullivan; Leslie A Crews; Elisabeth M Messmer; Gary N Foulks; Kelly K Nichols; Philipp Baenninger; Gerd Geerling; Francisco Figueiredo; Michael A Lemp
Journal:  Acta Ophthalmol       Date:  2012-12-28       Impact factor: 3.761

5.  Prevalence of myopia and hyperopia in 6- to 72-month-old african american and Hispanic children: the multi-ethnic pediatric eye disease study.

Authors: 
Journal:  Ophthalmology       Date:  2009-11-18       Impact factor: 12.079

6.  Assessment of the Incorporation of Patient-Centric Outcomes in Studies of Minimally Invasive Glaucoma Surgical Devices.

Authors:  Jimmy T Le; Shilpa Viswanathan; Michelle E Tarver; Malvina Eydelman; Tianjing Li
Journal:  JAMA Ophthalmol       Date:  2016-09-01       Impact factor: 7.389

7.  Etiology, prevalence, and treatment of dry eye disease.

Authors:  Johnny L Gayton
Journal:  Clin Ophthalmol       Date:  2009-07-14

Review 8.  Over the counter (OTC) artificial tear drops for dry eye syndrome.

Authors:  Andrew D Pucker; Sueko M Ng; Jason J Nichols
Journal:  Cochrane Database Syst Rev       Date:  2016-02-23

9.  Developing core outcome sets for clinical trials: issues to consider.

Authors:  Paula R Williamson; Douglas G Altman; Jane M Blazeby; Mike Clarke; Declan Devane; Elizabeth Gargon; Peter Tugwell
Journal:  Trials       Date:  2012-08-06       Impact factor: 2.279

10.  Why clinical trial outcomes fail to translate into benefits for patients.

Authors:  Carl Heneghan; Ben Goldacre; Kamal R Mahtani
Journal:  Trials       Date:  2017-03-14       Impact factor: 2.279
View more
  3 in total

1.  Report From the National Eye Institute Workshop on Neuro-Ophthalmic Disease Clinical Trial Endpoints: Optic Neuropathies.

Authors:  Leonard A Levin; Mohor Sengupta; Laura J Balcer; Mark J Kupersmith; Neil R Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-11-01       Impact factor: 4.799

2.  The Efficacy of Clinical Tests to Diagnose Evaporative Dry Eye Disease Related to Meibomian Gland Dysfunction.

Authors:  Jerry R Paugh; Tiffany Nguyen; Alan Sasai; Elaine Chen; Melinda Thomas De Jesus; Justin Kwan; Andrew Loc Nguyen; Marjan Farid; Sumit Garg; James V Jester
Journal:  J Ophthalmol       Date:  2022-02-10       Impact factor: 1.909

3.  Outcome choice and definition in systematic reviews leads to few eligible studies included in meta-analyses: a case study.

Authors:  Ian J Saldanha; Kristina B Lindsley; Sarah Money; Hannah J Kimmel; Bryant T Smith; Kay Dickersin
Journal:  BMC Med Res Methodol       Date:  2020-02-11       Impact factor: 4.615
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.